Confirm Cancer-Associated LEMS with a VGCC-Ab test, both P/Q and N types

/test

Cancer-Associated LEMS Resources

Access and download useful educational tools and resources about Cancer-Associated LEMS

MORE LEMS WEBINAR CONTENT AVAILABLE NOW ON OncLive®

Stephen Vernino, MD, PhD
Department of Neurology
UT Southwestern Medical Center
Dallas, Texas

David Gerber, MD
Division of Hematology/Oncology
UT Southwestern Medical Center
Dallas, Texas

Small Cell Lung Cancer and Lambert-Eaton Myasthenic Syndrome

A Multichapter Review

EP. 1

Defining LEMS

(Gerber)

EP. 2

Testing for LEMS

(Vernino)

EP. 3

LEMS Case Review

(Vernino)

EP. 4

LEMS Diagnosis: Patient Presentation and Testing

(Gerber)

EP. 5

Front-line Treatment Options for SCLC

(Gerber)

EP. 6

Treatment Options for LEMS

(Vernino)

EP. 7

Monitoring Patients with SCLC and LEMS

(Gerber)

EP. 8

Case Review: Small Cell Lung Cancer Following LEMS

(Gerber)

EP. 9

Clinical Pearls and the Future of LEMS

(Vernino)

Visit OncLive® to view these episodes

Autonomic Symptoms May Suggest Paraneoplastic Neurological Syndromes in Small Cell Lung Cancer

Download this scientific poster that describes a retrospective observational study of US healthcare claims of patients with small cell lung cancer (SCLC). First presented at the NCCN Annual Conference in April 2024, the poster found an association between SCLC and paraneoplastic syndromes based on the presence of autonomic symptoms.

Download Poster

Lambert-Eaton Myasthenic Syndrome Is Underrecognized in Small Cell Lung Cancer: An Analysis of Real-World Data

Download this scientific poster that provides an analysis of the frequency of Lambert-Eaton myasthenic syndrome (LEMS) diagnoses among US patients with small cell lung cancer (SCLC). First presented at the World Congress of Lung Cancer (WCLC) in September 2023, the poster describes a significant underrecognition of LEMS in patients with SCLC.

Download Poster

Prevalence of Small Cell Lung Cancer in US Patients With Lambert-Eaton Myasthenic Syndrome: A Contemporary Real-World Data Analysis

Download this scientific poster that provides an analysis of the frequency of LEMS screening in SCLC patients in the US. First presented at the Myasthenia Gravis Foundation of America (MGFA) Scientific Session at AANEM 2023, the poster includes data that suggest patients with SCLC are not being adequately screened for LEMS.

Download Poster

References:

  1. Gandhi L, Johnson BE. Paraneoplastic syndromes associated with small cell lung cancer. J Natl Compr Canc Netw. 2006;4(6):631-638.
  2. Titulaer MJ, Lang B, Verschuuren JJ. Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies. Lancet Neurol. 2011;10(12):1098-1107.
  3. Gilhus NE. Lambert-Eaton myasthenic syndrome; pathogenesis, diagnosis, and therapy. Autoimmune Dis. 2011;2011:973808.
  4. Bebb DG, Murray C, Giannopoulou A, Felip E. Symptoms and experiences with small cell lung cancer: a mixed methods study of patients and caregivers. Pulm Ther. 2023;9:435-450.
  5. Yoon CH, Owusu-Guha J, Smith A, Buschur P. Amifampridine for the management of Lambert-Eaton myasthenic syndrome: a new take on an old drug. Ann Pharmacother. 2020;54(1):56-63.
  6. Wirtz PW, Smallegange TM, Wintzen AR, Verschuuren JJ. Differences in clinical features between the Lambert-Eaton myasthenic syndrome with and without cancer: an analysis of 227 published cases. Clin Neurol Neurosurg. 2002;104(4):359-363.
  7. Hartmann GG, Sage J. Small-cell lung cancer neuronal features and their implications for tumor progression, metastases, and therapy. Mol Cancer Res. 2024;22(9):787-795.
  8. Maddison P, Gozzard P, Grainge MJ, Lang B. Long-term survival in paraneoplastic Lambert-Eaton myasthenic syndrome. Neurology. 2017;88:1-6.
  9. Titulaer MJ, Verschuuren JJ. Lambert-Eaton myasthenic syndrome: tumor versus nontumor forms. Ann N Y Acad Sci. 2008;1132:129-34.
  10. Lipka AF, Boldingh MI, van Zwet EW, et al. Long-term follow-up, quality of life, and survival of patients with Lambert-Eaton myasthenic syndrome. Neurology. 2020;94(5):e511-e520.
  11. ARUP Laboratories. Accessed August 2, 2025. https://ltd.aruplab.com/Tests/Pub/3002046
  12. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Small Cell Lung Cancer V.1.2026. © National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed August 8, 2025. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
  13. Kunii E, Owaki S, Yamada K, et al. Lambert-Eaton myasthenic syndrome caused by atezolizumab in a patient with small-cell lung cancer. Intern Med. 2022;61:1739-1742.
  14. Giannoccaro MP, Avoni P, Liguori R. Presynaptic paraneoplastic disorders of the neuromuscular junction: an update. Brain Sci. 2021;11(8):1035.
  15. Titulaer MJ, Lang B, Verschuuren JJ. Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies. Lancet Neurol. 2011; Appendix:1-4.
  16. Harms L, Sieb JP, Williams AE, et al. Long-term disease history, clinical symptoms, health status, and healthcare utilization in patients suffering from Lambert Eaton myasthenic syndrome: results of a patient interview survey in Germany. J Med Econ. 2012;15(3):521-530.
  17. Morrell D, Drapkin B, Shechter G, Grebla R. Lambert-Eaton myasthenic syndrome is underrecognized in small cell lung cancer: an analysis of real-world data. Presented as a poster at the International Association for the Study of Lung Cancer (IASLC) – WCLC Annual Meeting 2023. September 9-12, 2023, Singapore.
  18. Sanders DB. Lambert-Eaton myasthenic syndrome: diagnosis and treatment. Ann N Y Acad Sci. 2003;998:500-508.
  19. Catterall WA. Voltage-gated calcium channels. Cold Spring Harb Perspect Biol. 2011;3:a003947.
  20. Schampel A, Kuerten S. Danger: High voltage—the role of voltage-gated calcium channels in central nervous system pathology. Cells. 2017;6(4):43.
  21. Loser V, Vicino A, Théaudin M. Autoantibodies in neuromuscular disorders: a review of their utility in clinical practice. Front Neurol. 2024;15:1495205.
  22. Alhammad RM, Alshamian Y, Alneseyan R, Al-Harbi TM, Ajhijab A, Alanazy MH. Clinical presentations, electrophysiologic features, and long-term follow-up in Lambert-Eaton myasthenic syndrome: a series of six patients. Front Neurol. 2024;15:1525155.
  23. Labcorp. Voltage-gated calcium channel antibody (VGCCA). Accessed August 16, 2025. https://www.labcorp.com/tests/140640/voltage-gated-calcium-channel-antibody-vgcca
  24. Kesner VG, Shin JO, Dimachkie MM, Barohn RJ. Lambert-Eaton myasthenic syndrome. Neurol Clin. 2018;36(2):379-394.
  25. Silva T. Understanding lambert-eaton myasthenic syndrome: pathophysiology, diagnosis, and treatment. J Neurol Neurorehab Res. 2024;9(1):1-2.
  26. Ivanovski T, Miralles F. Lambert-Eaton myasthenic syndrome: early diagnosis is key. Degener Neurol Neuromuscul Dis. 2019;13:27-37.

Connect with us

For US Residents Only

Privacy Policy

Contact Catalyst Pharmaceuticals

© 2025 Catalyst Pharmaceuticals, Inc. All Rights Reserved. LEM-0463-4 August 2025

Corner Rock

You are now leaving the CancerAssociatedLEMS.com website

Continue